- Home
- SITC vs ARVN Comparison
SITC vs ARVN Comparison
Compare SITC & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SITC
- ARVN
- Stock Information
- Founded
- SITC 1965
- ARVN 2015
- Country
- SITC United States
- ARVN United States
- Employees
- SITC N/A
- ARVN N/A
- Industry
- SITC Real Estate Investment Trusts
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- SITC Real Estate
- ARVN Health Care
- Exchange
- SITC Nasdaq
- ARVN Nasdaq
- Market Cap
- SITC 494.6M
- ARVN 456.2M
- IPO Year
- SITC 1993
- ARVN 2018
- Fundamental
- Price
- SITC $8.74
- ARVN $7.74
- Analyst Decision
- SITC Buy
- ARVN Buy
- Analyst Count
- SITC 7
- ARVN 22
- Target Price
- SITC $30.29
- ARVN $20.21
- AVG Volume (30 Days)
- SITC 1.0M
- ARVN 1.3M
- Earning Date
- SITC 10-29-2025
- ARVN 10-29-2025
- Dividend Yield
- SITC 54.41%
- ARVN N/A
- EPS Growth
- SITC N/A
- ARVN N/A
- EPS
- SITC 6.74
- ARVN N/A
- Revenue
- SITC $173,351,000.00
- ARVN $372,800,000.00
- Revenue This Year
- SITC N/A
- ARVN $4.87
- Revenue Next Year
- SITC $2.31
- ARVN N/A
- P/E Ratio
- SITC $1.27
- ARVN N/A
- Revenue Growth
- SITC N/A
- ARVN 299.57
- 52 Week Low
- SITC $8.69
- ARVN $5.90
- 52 Week High
- SITC $18.15
- ARVN $29.61
- Technical
- Relative Strength Index (RSI)
- SITC 27.51
- ARVN 53.61
- Support Level
- SITC $8.92
- ARVN $7.58
- Resistance Level
- SITC $9.09
- ARVN $8.23
- Average True Range (ATR)
- SITC 0.25
- ARVN 0.38
- MACD
- SITC -0.21
- ARVN 0.00
- Stochastic Oscillator
- SITC 1.22
- ARVN 36.36
About SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.